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A B S T R A C T
Depression affects over 40% of people with HIV (PHIV) in low- and middle-income countries, and over half of
PHIV report HIV-related internalized stigma. However, few longitudinal studies of PHIV have examined the
relationship between HIV-related stigma and depression. Data were analyzed from the 2007-15 Uganda AIDS
Rural Treatment Outcomes (UARTO) Study, a cohort of 454 antiretroviral therapy (ART)-naïve PHIV (68%
women) starting ART. Our primary outcome was depression symptom severity over the first two years of ART,
measured using a locally adapted version of the Hopkins Symptom Checklist; our primary exposure was the 6-item
Internalized AIDS-Related Stigma Scale. Both scores were measured at enrollment and at quarterly follow-up
visits. We fit linear generalized estimating equations (GEE) regression models to estimate the association be-
tween stigma and depression symptom severity, adjusting for potential confounders. We included a stigma  time
product term to assess the modifying effect of ART on the association between internalized stigma and depression
symptom severity. UARTO participants had a median age of 32 years and median enrollment CD4 count of
217 cells/mm3. Both depression symptom severity and internalized stigma declined on ART, particularly during
the first treatment year. In multivariable regression models, depression symptom severity was positively associ-
ated with internalized stigma (b ¼ 0.03; 95% confidence interval [CI], 0.02 to 0.04) and negatively associated
with ART duration >6 months (b ¼ 0.16; 95% CI, 0.19 to 0.13). The estimated product term coefficient was
negative and statistically significant (P ¼ 0.004), suggesting that the association between internalized stigma and
depression symptom severity weakened over time on ART. Thus, in this large cohort of PHIV initiating ART in
rural Uganda, depression symptom severity was associated with internalized stigma but the association declined
with time on ART. These findings underscore the potential value of ART as a stigma reduction intervention for
PHIV, particularly during early treatment.
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1. Introduction
Depression is highly prevalent among people with HIV (PHIV),
affecting approximately one-third of all PHIVworldwide and over 40% of
PHIV in low- and middle-income countries (Kinyanda et al., 2011;
Lowther et al., 2014; Nakasujja et al., 2010; Nakimuli-Mpungu et al.,
2011; Tsai, 2014). In addition, as many as half of all PHIV report
HIV-related internalized stigma (Lowther et al., 2014; Pantelic et al.,
2015; Remien & Mellins, 2007; Tsai, 2015), which tends to inhibit
serostatus disclosure to partners and family members (Simbayi et al.,
2007; Tsai et al., 2013a) and, erodes social support (Logie & Gadalla,
2009; Rueda et al., 2016; Takada et al., 2014), and is associated with
depression (Akena et al., 2012; Ashaba et al., 2018; Boyes et al., 2020;
Rueda et al., 2016; Simbayi et al., 2007). Internalized stigma, concep-
tualized here as self-defacing internal representations of what it means to
be a person living with HIV (Kalichman et al., 2009), is negatively
associated with other important outcomes, including poor adherence to
antiretroviral therapy (ART) and HIV disease control (Earnshaw et al.,
2013; Katz et al., 2013; Pantelic et al., 2020; Tsai et al., 2010; Turan et al.,
2019), and quality of life (Onyebuchi-Iwudibia & Brown, 2014).
The framework that organizes our conceptualization of the relation-
ship between HIV-related internalized stigma and depression is based on
the idea that the internalization of stigma can lead to depressive symp-
toms, due to a constellation of self-defacing self-perceptions, including
feelings of worthlessness, shame, and guilt (Kalichman et al., 2009).
There is mounting evidence that HIV-related stigma can become inter-
nalized and that, once internalized, stigma can adversely affect mental
health (Simbayi et al., 2007; Tsai et al., 2012). Stigma is multifaceted,
embedded in social and structural systems, and it is natural for people to
internalize negative messages conveyed by people, norms, policies,
and/or institutions (Link et al.,; Evans-Lacko et al., 2012; Corrigan et al.,
2004; Tsai et al., 2019). Although internalized stigma is only one
dimension of stigma, studies conducted in a range of settings suggest that
internalized stigma can account for a significant and unique proportion
of depressive symptoms, including among PHIV in North America (Lee
et al., 2002), South Africa (Simbayi et al., 2007), and Uganda (Tsai et al.,
2012). These findings suggest that internalized HIV-related stigma plays
a key role in depressive symptoms and emotional wellbeing among PHIV
across cultures. People with HIV can also perceive and anticipate rejec-
tion from others on the basis of their serostatus (perceived and antici-
pated stigma) (Tsai et al., 2021); experience behavioral manifestations of
stigma directly from others (enacted stigma) (Scambler & Hopkins,
1986); and experience normative or codified manifestations of stigma
directly through policies and institutions (Corrigan et al., 2004). All of
these facts of stigma are also associated, in the context of HIV, with poor
HIV and health care outcomes. Further, the stigma of HIV can also
intersect with the stigma attached to other marginalized identities,
compounding the nature of the stigma felt or experienced and the
resulting adverse health and mental health outcomes (Goodin et al.,
2018; Logie et al., 2011, 2019). In this analysis, we focused on one
dimension of stigma – internalized stigma – given its substantive role in
the genesis of depression among people with HIV(10, 24, 29).
The advent of ART has been conceptualized as a population-level anti-
stigma intervention, given its role in attenuating the fear associated with
an HIV diagnosis and in transforming HIV from a terminal illness into a
chronic illness (Farmer et al., 2001a, 2001b). Consistent with this argu-
ment, several population-level studies have found the introduction and
scale-up of ART to be associated with decreases in stigmatizing attitudes
toward PHIV and in perceived stigma attached to HIV disease (Chan
et al., 2015a; Wolfe et al., 2008). In addition to the direct effects of ART
on stigma, ART may also modify the relationship between stigma and
other psychosocial outcomes of interest, for example, by increasing
weight gain, enhancing body self-image, and improving overall health
and economic productivity (Thirumurthy et al., 2008; Venkataramani
et al., 2014) – and thereby weakening the adverse mental health effects
of internalized stigma (Tsai et al., 2013b). Although ART may be an
important treatment for HIV-related internalized stigma, larger social
and structural contexts amplify stigma, and stigma operates on many
levels, intersecting with other identities including gender identity, sexual
orientation, socioeconomic status, and work identity. Thus, HIV-related
stigma may be mitigated by ART due to reduced fear of morbidity and
infection, but is also grounded in pre-existing social inequalities, cultural
norms and values, including misinformation and fear, which may act as
barriers to ART access (Stangl et al., 172019). Thus, although ART may
address some aspects of stigma, other stigma dimensions and intersecting
forms of stigma exist.
However, the longitudinal relationship between HIV-related inter-
nalized stigma and depression is incompletely characterized. While HIV-
related internalized stigma is known to decline during ART in part
through improved self-image and feelings of empowerment, particularly
in the first 2 years of treatment (Tsai et al., 2013c), and ART is associated
with improved psychological wellbeing (Martinez et al., 2014; Tsai et al.,
2013c; Wagner et al., 2012), depression remains highly prevalent among
PHIV on ART (Tsai, 2014). Further, in some studies depressive symptoms
have been shown to increase after 12 months on ART (Pearson et al.,
2009; Peltzer & Ramlagan, 2011).
In this secondary analysis of data from a large cohort of ART-naïve
PHIV initiating ART in rural Uganda (Uganda AIDS Rural Treatment
Outcomes [UARTO]), we sought to estimate the association between
internalized stigma and depression symptom severity during the first two
years of treatment. Additional studies of related topics have been carried
out in this population (Tsai et al., 2012, 2013a, 2013d). Specifically, our
aims were to estimate the association between internalized stigma and
depression symptom severity, and to assess the extent to which duration
of ART modifies the estimated association. We hypothesized that inter-
nalized stigma would be positively associated with depression symptom
severity and that the magnitude and strength of this association would
decline over time on ART. If shown to be true, our hypothesis would
identify improvements in HIV-associated depressive symptoms as a sig-
nificant collateral benefit of ART, and also emphasize the importance of
early and sustained ART treatment, especially in PHIV with clinically
significant mental health problems.
2. Material and methods
2.1. Study design
Data for this analysis were obtained from the Uganda AIDS Rural
Treatment Outcomes (UARTO, NCT01596322) study, a cohort of treat-
ment-naïve PHIV initiating ART between 2005 and 2013 enrolled to
elucidate the social and biological correlates of ART adherence. Partici-
pants were recruited from the Mbarara Immune Suppression Syndrome
(ISS) Clinic, an ART clinic located inMbarara, Uganda, 270 km southwest
of Kampala. The clinic is representative of other regional HIV clinics,
receiving program funding frommultilateral programs including the U.S.
President's Emergency Plan for AIDS Relief (PEPFAR) (Geng et al., 2010).
ISS patients were eligible for UARTO participation if they tested positive
for HIV infection, were newly initiating ART, were 18 years of age, and
lived within 60 km of the clinic. Participants who declined to initiate ART
or who lived outside of the catchment area were excluded. For this
analysis we further excluded any participants who were missing data on
the primary exposure and outcome of interest within 3 months of ART
initiation.
Before initiating ART, participants were required to complete two
pre-treatment counseling sessions conducted by clinic staff employees
trained as counselors (Siedner et al., 2012). Counseling sessions focused
on treatment schedules, potential toxicities, ART resistance resulting
from suboptimal adherence, and managing missed doses. Adherence
counseling was generally not provided at subsequent visits. At the
pre-treatment baseline visit, participants underwent phlebotomy and
structured interviews conducted by a research assistant in the local lan-
guage, Runyankole.
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The most common ART regimens at initiation were zidovudine/
lamivudine/nevirapine (AZT/3TC/NVP), stavudine/lamivudine/nevira-
pine (D4T/3TC/NVP), and tenofovir/lamivudine/efavirenz (TDF/3TC/
EFV), used by 62, 26 and 10% of participants, respectively. Thus, nevi-
rapine- and efavirenz-containing regimens accounted for 98% of all ART.
Once a participant was stable on a specific ART regimen, the participant
returned at regular intervals for usual care with a medical/clinical officer
or a nurse. Every 3–4 months, UARTO participants underwent repeat
phlebotomy and a structured interview. Internalized stigma assessments
were added to the UARTO study in 2007. All study participants with at
least one internalized stigma baseline screenmeasurement were included
in this current analysis. The cohort was followed until 2015 to ensure at
least 24 months of follow-up for the participants enrolled in 2013.
Written or thumbprint-mark consent was obtained from all study par-
ticipants. Ethical approval was obtained from the University of California
at San Francisco Committee on Human Research, the Partners Human
Research Committee, and the Mbarara University of Science and Tech-
nology Research Ethics Committee. Consistent with national guidelines,
we also obtained clearance for the study from the Uganda National
Council of Science and Technology.
2.2. Measures
The primary outcome was depression symptom severity, measured by
the depression subscale of the Hopkins Symptom Checklist (HSCL)
(Derogatis et al., 1974). The original subscale consists of 15 items. We
removed four somatic items (“feeling low in energy, slowed down,”
“feeling fidgety,” “poor appetite,” and “having difficulty falling or staying
asleep”) to minimize overlap between depressive symptoms of depres-
sion and HIV disease (Kalichman et al., 2000), and added one item to
capture a locally validated concept indicative of depression in Uganda
(“feeling like I don't care what happens to my health”) (Bolton & Ndo-
goni, 2001). The modified depression subscale is scored by averaging
across the 12 items (Bolton&Ndogoni, 2001; Tsai et al., 2012). To define
a positive screen for clinically significant symptoms of depression
(“probable depression”), we used the cutoff of >1.75 used by Hesbacher
et al. (Hesbacher et al., 1980), which has previously been used in this
population (Tsai et al., 2012). The primary exposure was internalized
stigma, measured by the IARSS (Kalichman et al., 2009), a six-item scale
measuring internalized stigma and associated self-defacing internal
representations of the self. The IARSS was developed using three inde-
pendent samples of PHIV in South Africa, Swaziland, and the United
States, and has a coherent internal structure, good reliability, and
construct validity among PHIV in Uganda (Tsai et al., 2013a, 2013d).
Each item has two response options (“Yes” or “No”), and higher IARSS
scores indicate a greater degree of internalized stigma. The IARSS is one
of the most widely used scales to assess internalized HIV-related stigma
(Pantelic et al., 2015) and has been validated in numerous settings
throughout sub-Saharan Africa (Geibel et al., 2020; MacLean &
Wetherall, 2021).
The HSCL and IARSS were administered at the baseline enrollment
visit and subsequent quarterly follow-up visits. For participants missing
either measure at enrollment, the score from the earliest visit was used if
measured within one month of starting ART. For follow-up visits, mea-
surements within three months of each visit were used. Visits without an
HSCL and IARSS score within three months of baseline enrollment were
excluded from the analysis.
Socio-demographic variables collected at the baseline visit included
age, sex, primary education completion, marital status, household asset
wealth (Smith et al., 2020), harmful alcohol consumption (3-item con-
sumption subset of the Alcohol Use Disorders Identification Test
[AUDIT-C]) (Adong et al., 2019; Asiimwe et al., 2015; Bradley et al.,
2003; Bush et al., 1998; Thakarar et al., 2016), and employment status.
For the asset wealth measure, we applied principal components analysis
to 25 binary variables for household-owned assets and housing charac-
teristics (Filmer & Pritchett, 2001). The first principal component was
retained and used to define the wealth index and was used as a contin-
uous variable in regression models, with higher values indicating greater
asset wealth.
For analysis purposes, the cohort was divided into those enrolled
during 2007–2009 (earlier group) and those enrolled during 2010–2013
(later group). This stratification was performed because Ugandan Na-
tional ART Treatment guidelines changed in 2009, increasing the CD4
threshold for ART initiation from <250 to <350 cells/mm3. Starting in
2010, large numbers of participants with CD4 counts >250 cells/mm3
were enrolled into UARTO.
2.3. Statistical analysis
Descriptive statistics were used to characterize the cohort, comparing
the earlier (2007–2009) and later (2010–2013) participant groups. For
the primary analysis characterizing the relationship between internalized
stigma and depression symptom severity, we fit a linear generalized
estimating equations (GEE) regression model with HSCL score as a
continuous outcome variable and IARSS stigma score as a continuous
exposure variable, using cluster-correlated robust estimates of variance
to account for repeated measures within participants over time. Time on
ART was dichotomized into >6 months versus 6 months. In sensitivity
analyses, we fit a logistic GEE regression model specifying probable
depression (HSCL score >1.75) as the dichotomous outcome and any
internalized stigma (IARSS >0) as the dichotomous exposure. An addi-
tional linear GEE model was fitted examining depression symptom
severity over 4-month intervals after starting ART. We then restricted the
GEE analyses to participants with at least 24 months in follow-up on ART,
modeling depression and internalized stigma as continuous and cate-
gorical variables. All estimates were adjusted for the sociodemographic
variables described above, continuous CD4 T-cell count (cells/mm3),
ART duration, and year of cohort entry to account for secular trends in
HIV-associated internalized stigma over time.
To estimate the extent to which ART modified the association be-
tween internalized stigma and depression symptom severity, we specified
time on ART as a continuous variable (in months) and then included a
stigma  time product term. A negative coefficient was interpreted as
evidence that the estimated association between internalized stigma and
depression symptom severity declined (i.e., weakened) over time on
ART.
To assess the robustness of our findings to unobserved confounding,
we used methods proposed by VanderWeele et al. (VanderWeele& Ding,
2017). We performed an e-value analysis to estimate the minimum
strength of association on the risk ratio scale that would be needed for an
unobserved confounder to have with both the exposure (internalized
stigma) and the outcome (depression symptom severity), assuming the
covariates as measured, to explain away the observed association. The
e-value quantifies the extent to which unobserved confounding might
contribute to the findings. Analyses were conducted using Stata version
16.0 (StataCorp LP, College Station, TX, USA) and the figure was
generated using GraphPad Prism 8.4.3 (GraphPad Software, San Diego,
CA, USA).
3. Results
A total of 454 participants were enrolled. Cohort characteristics are
presented in Table 1, grouped by year of enrolment (2007–2009 versus
2010–2013). Overall, 407 (90%) participants were retained in follow-up
for 24 months or longer, similar for both groups (P ¼ 0.95). The median
enrollment age was 32 years (interquartile range [IQR] 27–40). Most
were women (68%). The median baseline CD4 count was 157 cells/mm3
among participants enrolled in the earlier group versus 292 cells/mm3
among participants enrolled in the later group (P < 0.001). No statisti-
cally significant differences were observed in mean log10 viral load (P ¼
0.16). A total of 427 (94%) participants had a baseline HSCL score, and
413 (91%) had a baseline IARSS score, measured within one month of
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starting ART. The median baseline IARSS score was 1 among participants
enrolled in the earlier group versus 2 among participants enrolled in the
later group (P ¼ 0.05). The proportion with probable depression was
similar in a comparison of the earlier versus later groups (24% versus
26%, P ¼ 0.63). The overall proportion with probable depression
decreased rapidly during the first year of treatment, to 6% at 12 months
and to 4% at 24 months. Paralleling this trend, the mean depression
symptom severity score declined rapidly during treatment. The mean
internalized stigma score also declined during this time (Fig. 1).
Our primary multivariable linear GEE regression model demonstrated
that depression symptom severity was positively associated with greater
internalized stigma (b ¼ 0.03; 95% confidence interval [CI], 0.02–0.04)
(Table 2). The magnitude of this estimate can be appreciated by
comparing it with the mean baseline HSCL of 1.50: an individual with a
maximum IARSS score of 6 would have a predicted HSCL score of 1.73, or
approximately 15% higher relative to the baseline mean. The depression
symptom severity was also negatively associated with ART treatment
duration >6 months (b ¼ 0.16; 95% CI, 0.19 to 0.13). Sensitivity
analysis using a dichotomous outcome variable (HSCL score cutoff of
>1.75, indicating probable depression) yielded similar results. Addi-
tional analysis demonstrated a stigma  gender product term was not
statistically significant.
When stratified by duration of ART, the estimated association
remained statistically significant, but the magnitude decreased over time.
In a linear GEE regression model specifying a product term for
stigma  ART duration, the interaction was negative and statistically
significant (b ¼ 0.02, 95% CI -0.04 to 0.007, P ¼ 0.004), suggesting
Table 1
Participant characteristics as measured at the baseline interview, by year of










for 12 months on
ART
432 (95) 181 (93) 251 (97) 0.05
Retained in follow-up
for 24 months on
ART
407 (90) 175 (90) 232 (90) 0.95
Age in years, median
(IQR)
32 (27, 40) 34 (28, 39) 31 (26, 40) 0.19
Women 308 (68) 133 (68) 175 (68) 0.89
Married 247 (54) 90 (46) 157 (61) 0.002
Christian religious
affiliation
408 (90) 175 (90) 233 (90) 0.94
Beyond primary
education
123 (27) 44 (23) 79 (31) 0.06
Asset wealth indexa <0.001
Poorest quartile 110 (24) 66 (34) 44 (17)
Poorer 113 (25) 50 (26) 63 (24)
Less poor 118 (26) 45 (23) 73 (28)
Least poor quartile 113 (25) 34 (17) 79 (31)
Employed outside the
home




172 (38) 81 (42) 91 (35) 0.14
BMI category 0.005
<18 41 (9) 24 (13) 17 (7)
18–25 316 (70) 139 (73) 177 (68)









<100 76 (17) 50 (26) 26 (10)
100–250 191 (42) 115 (59) 76 (29)
350 94 (21) 11 (6) 83 (32)
HIV viral load (log10),
mean (SD)
4.8 (0.9) 4.9 (0.8) 4.8 (0.9) 0.16
Probable depression
(HSCL score >1.75)
107 (25) 40 (24) 67 (26) 0.63
IARSS (stigma) score,
median (IQR)
1 (0, 3) 1 (0, 3) 2 (0, 4) 0.05
Table 1 footnotes: ART ¼ antiretroviral therapy; BMI ¼ body mass index in kg/
m2; CD4 ¼ CD4þ T lymphocyte count in cells/mm3; HSCL ¼ Hopkins Symptom
Checklist; IARSS ¼ Internalized AIDS-Related Stigma Scale; IQR ¼ interquartile
range; SD ¼ standard deviation; UARTO ¼ Uganda AIDS Rural Treatment Out-
comes.
Results listed as n (%) unless otherwise noted. Tests of association were per-
formed using Chi-squared, Wilcoxon rank sum, and t-tests.
a The asset index variable was calculated using principal components analysis.
By definition, the within-cohort mean is equal to zero. Positive scores indicate
increasing wealth, and negative scores indicate decreasing wealth.
Fig. 1. Unadjusted mean stigma (IARSS) and depressive symptom (HSCL)
scores by ART duration.
Fig. 1 legend. Depression symptom severity was measured by the HSCL on the
continuous scale, with a higher score indicating more severe depressive symp-
toms. Internalized stigma was measured by the IARSS on the continuous scale,
with a higher score indicating a greater degree of internalized stigma. Bars
represent standard errors.
Table 2
Correlates of depression symptom severity over the first 24 months of antire-
troviral therapy (N ¼ 454). Using a multivariable linear GEE regression model,
both internalized stigma (IARSS) and depression symptom severity (HSCL) were
modeled as continuous variables. The estimated regression coefficient (b) rep-
resents the change in depression symptom severity associated with each 1-point






IARSS score 0.03 0.02, 0.04 <0.001
>6 months on ART (versus 6
months)
0.16 0.19, 0.13 <0.001
Year of cohort enrolment 0.006 0.02, 0.007 0.38
Female sex (versus male) 0.12 0.07, 0.17 <0.001
Age 0.002 0.0003, 0.005 0.08
Asset index quartilea
Poorest quartile Reference
Poorer 0.0008 0.07, 0.06 0.98
Less poor 0.04 0.10, 0.02 0.23
Least poor quartile 0.05 0.11, 0.02 0.18
CD4 count 0.00009 0.00004, 0.0002 0.19
Primary or no formal education
(versus more than primary
education)
0.01 0.04, 0.07 0.61
Married (versus never married,
separated/divorced, or widowed)
0.002 0.04, 0.05 0.92
Table 2 footnotes: CI¼ confidence interval; HSCL¼Hopkins Symptom Checklist;
IARSS ¼ Internalized AIDS-Related Stigma Scale; ART ¼ antiretroviral therapy;
CD4 ¼ CD4þ T lymphocyte count in cells/mm3.
a The asset index variable was calculated using a principal components anal-
ysis. By definition, the within-cohort mean is equal to zero. Positive scores
indicate increasing wealth, and negative scores indicate decreasing wealth.
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that the estimated association between internalized stigma and depres-
sion symptom severity was modified by ART treatment duration, i.e., the
association between internalized stigma and depressive symptoms
weakened over time on ART. The estimated association between inter-
nalized stigma and depression symptom severity was strongest during
months 0–4 of ART (b ¼ 0.04, 95% CI 0.02–0.06, P < 0.001) and
weakened over successive intervals on ART (Table 3). By 24 months of
treatment, the estimated association between internalized stigma and
depression symptom severity was no longer statistically significant.
In a secondary analysis, we fit a multivariable logistic GEE regression
model showing that any internalized stigma was positively associated
with probable depression (adjusted odds ratio [AOR] ¼ 2.11; 95% CI,
1.56–2.84; P < 0.001) (Table 4). Using the odds ratio correction
described by VanderWeele (VanderWeele& Ding, 2017), we obtained an
e-value of 2.26. Thus, an unobserved confounder would require a
strength of association, on the risk ratio scale, with both internalized
stigma and probable depression of 2.26 each to shift our estimated as-
sociation to the null value of 1. This result suggests that confounding by
an unmeasured variable would need to be relatively strong in order to
fully explain the association between internalized stigma and probable
depression observed in our study.
4. Discussion
In this secondary analysis of data from a large cohort of ART-naïve
PHIV initiating ART in rural Uganda, we estimated a strong and statis-
tically significant association between internalized stigma and depres-
sion symptom severity over the first two years of treatment. As
hypothesized, we found that internalized stigma was robustly associated
with depression symptom severity at baseline, and that the magnitude
and strength of this association declined over time on ART. Our primary
finding is consistent with other reports that HIV-related internalized
stigma declines during ART, particularly in the first two years of treat-
ment (Tsai et al., 2013c). Multiple factors likely contribute to this
decline, including acceptance of HIV diagnosis, increasing medical and
social support over time, and improved physical health with ART and
ensuing economic and social reintegration (Thirumurthy et al., 2008;
Tsai et al., 2013b; Venkataramani et al., 2014). However, in contrast to
other studies demonstrating that depression continues to be prevalent
among PHIV on ART (Pearson et al., 2009; Peltzer & Ramlagan, 2011;
Tsai, 2014), we found a low (6%) prevalence of probable depression at 12
months, which remained low at 24 months (4%). In our analyses, we did
not see evidence of rebounding depressive symptoms at 24 months’
follow-up. The prevalence of probable depression at baseline enrollment
in this sample (24–26%) was comparable to other studies conducted in
sub-Saharan Africa (Tsai, 2014). It remains important to identify and
treat depressive symptoms among PHIV, because depression treatment
has been associated with improved mental health and, potentially,
HIV-related outcomes including improved ART uptake and adherence
and lower HIV viral load in several studies (Pence et al., 2015; Safren
et al., 2016; Tsai et al., 2010, 2013e).
The decrease in depressive symptoms we observed over time could be
due to ART therapy itself (Martinez et al., 2014), which could have a
positive impact on feelings of agency and hope among PHIV (Chan et al.,
2015a; Chan & Tsai, 2016; Tsai et al., 2013b). Furthermore, ART may
improve depressive symptoms through biologic and immunologic path-
ways. One such mechanism is through switching off the indoleamine 2,
3-dioxygenase-1 pathway activated by HIV viral products, leading to
reversal of tryptophan catabolism and a decreasing kynurenine:-
tryptophan ratio (Martinez et al., 2014). It is also possible that depressive
symptoms declined over time due to changes in ART regimens, based on
prior studies noting differences in depressive symptoms associated with
nevirapine-based ART compared to efavirenz-based ART (Chan et al.,
2015b; Chang et al., 2018). In this cohort, 88% of participants initiated
ART containing nevirapine, a proportion which likely decreased over
time as efavirenz use increased. However, decreases in depressive
symptoms could also be mediated by other explanatory factors, including
weight gain (which is viewed favorably in this setting (Wittenberg,
2013)) and attendant improvements in self-esteem, positive relationships
between clinic staff and caregivers, other components of the total
‘package’ of HIV care, and disclosure. It is nonetheless important to note
that time on ART and calendar time are collinear (Chan et al., 2015a;
Chan & Tsai, 2016), and thus regression to the mean as a potential
explanation for the observed reductions in depressive symptoms cannot
be completely ruled out. However, we believe this to be less likely given
that depression is known to impede engagement with HIV care (Cicho-
witz et al., 2017; Gardner et al., 2016; Kinyanda et al., 2018; Nakimu-
li-Mpungu et al., 2015; Zuniga et al., 2016). Nevertheless, given the way
in which the effect of internalized stigma on depression waned over time
on ART, we advocate for early and sustained ART adherence (Haberer
et al., 2017) and stigma reduction interventions for all PHIV (Stangl et al.,
Table 3
Association between internalized stigma (IARSS) and depressive symptom
severity (HSCL) over successive intervals of HIV antiretroviral therapy adjusting
for potential confounders, with IARSS score as a continuous exposure, and HSCL
score as a continuous outcome (N ¼ 454).
b coefficient (95% CI) P-value
Multivariable adjusted modelsa
0–4 months 0.04 (0.02, 0.06) 0.001
4–8 months 0.03 (0.008, 0.05) 0.006
8–12 months 0.02 (0.001, 0.04) 0.04
12–16 months 0.03 (0.009, 0.05) 0.004
16–20 months 0.03 (0.005, 0.05) 0.01
20–24 months 0.02 (0.003, 0.04) 0.02
 24 months 0.02 (0.008, 0.04) 0.20
Table 3 footnotes: CI¼ confidence interval; HSCL¼Hopkins Symptom Checklist;
IARSS ¼ Internalized AIDS-Related Stigma Scale.
a each row represents the output of a multivariable regression model, with the
cell displaying only the estimated association between internalized stigma
(IARSS) and depression symptom severity (HSCL) adjusted for year of enrollment
into cohort, age, gender, asset index quartile, CD4 count at baseline, educational
level, and marital status.
Table 4
Correlates of probable depression (HSCL >1.75) over the first 24 months of
antiretroviral therapy (N ¼ 454). Using a multivariable logistic GEE regression
model, both internalized stigma and depression symptom severity were modeled
as dichotomous variables (IARSS >0 and HSCL >1.75). The estimated regression
coefficients were exponentiated so that they could be interpreted as adjusted
odds ratios, which represents the change in odds of probable depression asso-
ciated with a unit change in the covariates.
Variable AOR 95% Confidence
Interval (CI)
P-value
IARSS score >0 (versus 0) 2.11 1.56, 2.84 <0.001
>6 months' on ART (versus 6 months) 0.32 0.24, 0.41 <0.001
Year of cohort enrolment 1.00 0.91, 1.11 0.92
Female sex (versus male) 2.70 1.65, 4.44 <0.001
Age 1.01 0.99, 1.03 0.37
Asset index quartilea
Poorest quartile 0.87 0.53, 1.43 0.59
Poorer 0.60 0.35, 1.03 0.06
Less poor 0.60 0.34, 1.05 0.07
CD4 count 1.00 1.00, 1.00 0.29
Primary or no formal education (versus
more than primary education)
0.91 0.58, 1.41 0.66
Married (versus never married,
separated/divorced, or widowed)
1.02 0.69, 1.51 0.92
Table 4 footnotes: AOR ¼ adjusted odds ratio; CI ¼ confidence interval; HSCL ¼
Hopkins Symptom Checklist; IARSS ¼ Internalized AIDS-Related Stigma Scale;
ART ¼ antiretroviral therapy; CD4 ¼ CD4þ T lymphocyte count (cells/mm3).
a The asset index variable was calculated using a principal components anal-
ysis. By definition, the within-cohort mean is equal to zero. Positive scores
indicate increasing wealth, and negative scores indicate decreasing wealth.
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2013). In addition to the negative correlation between depressive
symptoms and ART adherence, higher baseline internalized stigma scores
also predict poor adherence to ART over time (Turan et al., 2019),
reinforcing our conclusion that early interventions to reduce internalized
stigma in PHIV could lead to better outcomes over time. Fundamental
interventions are needed to identify and treat HIV infection early; to
promote increased access to ART, especially amongst socially marginal-
ized groups; and to sustain uninterrupted ART therapy over at least the
first two years after initiation. Interventions should be multi-level,
challenge stigmatizing community and institutional norms, and incor-
porate bi-directional learning involving stigmatized people in the process
(Rao et al., 2019). Such interventions may also need to account for
intersecting stigmas by incorporating outreach to specific marginalized
groups experiencing varying degrees of structural oppression in order to
engage PHIV in advocacy and leverage their strengths in coping, social
support, and solidarity (Charurat et al., 2015; Ogunbajo et al., 2020;
Papworth et al., 2013; Schwartz et al., 2015). However, even in pop-
ulations where ART has decreased internalized HIV-related stigma,
disclosure concerns may persist, especially among PHIV taking ART
(Chan et al., 2019). Furthermore, medication adherence may still be
affected by HIV-related internalized stigma, limiting the effectiveness of
ART on reducing stigma (Blake Helms et al., 2017; Katz et al., 2013; Tsai
et al., 2013a).
Strengths of our study include the large cohort size, high retention in
care over two years of follow-up, and regular assessment of both inter-
nalized stigma and depressive symptoms, reducing the potential to miss
rebounding depressive symptoms over time on ART. Furthermore,
mental health outcomes have been understudied in our study population,
PHIV in rural areas of sub-Saharan Africa. Limitations of our study
include the lack of an untreated control group and incomplete mea-
surement of other possible confounders of both internalized stigma and
depressive symptoms over time. The e-value quantifies the extent to
which unobserved confounding could potentially explain away the
observed findings. As a concrete example, data on coping/self-efficacy
were not collected in this cohort, so we could not adjust our estimates
for this important (and potentially confounding) variable. However, in
previously published studies (albeit conducted in different settings), the
estimated associations between coping and depression (AOR ¼ 0.54)
(Chaudoir et al., 2012) and between self-efficacy and internalized stigma
(AOR ¼ 0.65) (Li et al., 2011), when inverted, were smaller than the
estimated e-value of 2.26 – suggesting that our failure to adjust for
coping/self-efficacy would be unlikely to completely explain the
observed association. BMI data were also insufficient to integrate into the
manuscript analysis and make conclusions about the relationship be-
tween BMI and internalized stigma and related depressive symptoms.
Furthermore, we were unable to assess mediators of depressive symp-
toms, or to determine the impact of ART on depressive symptoms inde-
pendent of other elements of the HIV care ‘package’. In addition, we
focused on internalized stigma for this analysis, which represents only
one dimension of stigma. This focus provides a unidimensional and
individual-level picture of one aspect of stigma, one facet of the social
and structural production of stigma and its consequences. Additional
studies focused on other aspects of stigma will help provide a more
complete picture of HIV-related stigma in all its forms. Lastly, the original
study providing data for this analysis ended in 2015. Thus, although
HIV-associated stigma remains a significant problem for PHIV, it is
possible that internalization of stigma and its relationship to depressive
symptoms has changed with time.
5. Conclusions
Higher degree of internalized stigma was longitudinally associated
with higher depression scores in this large cohort of PHIV initiating ART.
Both depression symptom severity and internalized stigma declined on
ART, particularly during the first treatment year. The association be-
tween internalized stigma and depression symptom severity weakened
over time on ART. Our findings underscore the need for early and sus-
tained ART adherence for PHIV. Future research should examine the
separate contributions of ART and stigma reductionmeasures to reducing
depressive symptoms among PHIV, longer-term associations between
internalized stigma, ART, and depressive symptoms beyond two years on
ART; and how the relationship between internalized stigma and
depressive symptoms has evolved over time.
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